Bayer’s Sunharbo receives U.S. FDA approval as a once-daily blood thinner intended to reduce the risk of an additional stroke. Quartz reports the approval is based on trial results showing a 26% reduction in ischemic stroke.
BioPharma Dive frames the decision as a broader class milestone: Sunharbo is the first FDA nod for a “Factor XIa” inhibitor, a drug category researchers and clinicians have anticipated could improve stroke prevention. While both outlets focus on the same approval, Quartz emphasizes the trial’s measured stroke-risk reduction, whereas BioPharma Dive highlights the medication’s mechanism and the significance of it being the first in its class.